This argument is not limited to gene therapies, but would apply to pretty much every pharmaceutical product.
One issue is however that the actual costs are not so much in early R&D (what the publicly funded universities and hospitals are doing), but in the later stage (clinical trials) which needs deep pockets and appetite for risk, which only big pharma has, because they see a potential big payout.
Right. Because your average citizen has a few hundred thousand dollars for their rare congenital disease. My bet — just wild eyed speculation — is that most of this stuff is paid for by the govt through sone sort of insurance-like subsidy. That means the risk is really borne by the tax payer.
One issue is however that the actual costs are not so much in early R&D (what the publicly funded universities and hospitals are doing), but in the later stage (clinical trials) which needs deep pockets and appetite for risk, which only big pharma has, because they see a potential big payout.